An interesting idea was postulated recently by Ebuchi et al. [29], who reported that a thyrotropin-releasing hormone (TRH) stimulation test, conducted before the initiation of growth promoting treatment, could help to identify individuals who are at risk of central hypothyroidism due to rhGH therapy and could require L-thyroxine replacement therapy. This evidence concerns the gene TRH and Central hypothyroidism.